Biosimilar to Remicade
Blockbuster drug could be key to Humira’s successor.
Humira successor indicated for adults with inadequate response or intolerance to methotrexate.
While FDA approved the second biosimilar drug to Enbrel, the success of the medication hinges on a pending lawsuit.
FDA is warning about an increased risk of death and blood clots in the lungs in patients with rheumatoid arthritis taking a specific dosage of this drug.